National Institute for Health and Clinical Excellence (NICE)
NICE signals commitment to greater flexibility in its evaluation of promising new health technologies and making patient access fairer
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board yesterday (19 January 2022).
The changes will come into effect early next month for new evaluations and will give patients earlier access to innovative new treatments by allowing greater flexibility over decisions about value for money and consideration of a broader evidence base.
They cover how topics are chosen (topic selection), the steps and stages in each evaluation (processes), and how evidence is collected and considered (methods).
With extensive involvement from health system partners, industry, healthcare professionals, academia and patients, the changes signal how NICE is evolving alongside technological advances in healthcare and evidence to continue to deliver excellence for patients, the NHS and the life sciences industry.
Professor Gillian Leng CBE, NICE chief executive, said:
“Our vision at NICE is to be at the forefront of delivering access for patients in the NHS to valuable, evidence-based innovative medicines, medical devices and diagnostics. The changes that we are making will provide a robust foundation for our evaluations now and in the future and enable us to continue to lead the way in rapid, independent health technology assessments.
“But they are not the end of the story. In the short term, we will explore the impacts and benefits of the updated methods and processes. We need to ensure they are effectively implemented in order to realise the benefits for NICE, the NHS and the wider stakeholder community, as well as supporting the Government’s wider vision for life sciences.
“Going forward, NICE will adopt a more modular approach to updates to its methods and processes. This will enable us to be more agile and responsive, monitoring, reviewing and improving our methods and processes into the future, making sure they remain cutting edge as the healthcare landscape continues to evolve.”
Key changes being implemented are:
- Giving additional weight to health benefits in the most severe conditions to allow more equitable access to treatments for these conditions, not just to treatments used at the end-of-life.
- Adopting new approaches to the evidence NICE considers in its assessments. For example, NICE will expand on and improve how it considers real-world evidence from the lived experiences of patients.
- Allowing more flexibility for NICE’s independent committees in cases where its particularly difficult to generate enough evidence. Sometimes, research into conditions affecting children, rare diseases or where the new treatment is innovative or complex can be problematic. The changes will allow NICE’s committees to consider uncertainty appropriately and to manage the risks to patients and the NHS while preventing inappropriate barriers to valuable innovations.
- Adopting a clearer vision, principles and routing criteria for treatments for very rare diseases that NICE will evaluate under its Highly Specialised Technologies (HST) Programme. This will improve the efficiency, predictability and clarity when routing topics to the programme and build upon NICE’s ambition to provide fairer access to highly specialised medicines and treatments within the NHS.
- Earlier engagement with NHS England and NHS Improvement and companies about commercial/managed access proposals that allow NHS patients to receive a treatment while further data is collected on its effectiveness. There will also be greater clarity around the circumstances in which NICE committees can make a managed access recommendation.
Helen Knight, programme director in the Centre for Health Technology Evaluation at NICE, said:
“We’ve engaged extensively with our stakeholders throughout this process and we’ve listened to their concerns and taken on board many of their suggestions. I would like to thank all those organisations and individuals who have so generously given their time to help us deliver a blueprint for health technology evaluation that is truly collaborative and one which signals our commitment to making the journey for promising new health technologies even faster, and patient access fairer.”
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills20/05/2022 12:10:00
Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said
Draft NICE guidance recommends innovative technology used to establish whether breast cancer has spread17/05/2022 12:15:00
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread, after the technology was recommended in draft NICE guidance
More than 400 people could benefit from life-extending advanced lung cancer treatment after it was recommended for routine use on the NHS17/05/2022 11:15:00
Durvalumab recommended as an option for treating non-small-cell lung cancer (NSCLC).
Women with moderate to severe fibroids set to be offered new one-a-day treatment following final draft guidance from NICE16/05/2022 14:15:00
Around 4,500 women with uterine fibroids will be eligible for a new oral treatment after NICE recommended relugolix with estradiol and norethisterone acetate (also called Ryeqo and made by Gedeon Ritcher UK) in final draft guidance.
NICE outlines steps needed to put ME/CFS guideline into practice12/05/2022 16:10:00
NICE has today, International ME Awareness Day (Thursday, 12 May 2022) published its implementation statement which sets out the practical steps needed to put its recent guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) into
Healthier lifestyle can help to ease osteoarthritis symptoms says NICE03/05/2022 16:15:00
Exercise has an important role to play in helping people living with osteoarthritis NICE says in draft updated guidelines published recently (29th April 2022) on the care and management of people with the condition.
Over 700 people a year could benefit from a new potentially life-extending lung cancer drug which targets a specific genetic mutation14/04/2022 16:10:00
New potentially life-extending lung cancer drug which targets a specific genetic mutation recommended by NICE.
NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance.13/04/2022 11:15:00
Two new antimicrobial drugs – cefiderocol and ceftazidime–avibactam – are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE yesterday (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.